Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

January 30, 2026

Study Completion Date

July 31, 2027

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
BIOLOGICAL

Epcoritamab

Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.

DRUG

Lenalidomide

Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.

Trial Locations (74)

53188

UW Cancer Center at ProHealth Care, Waukesha

Unknown

Kepler Universitätsklinikum, Linz

LKH - Universitätsklinikum der PMU Salzburg, Salzburg

Klinikum Wels-Grieskirchen GmbH, Wels

Institut Jules Bordet, Anderlecht

ZNA, Antwerp

UZ Brussels, Jette

UZ Leuven, Leuven

AZ Delta, Roeselare

Vitaz, Temse

AZ Turnhout - Campus Sint-Elisabeth, Turnhout

Fakultni nemocnice Hradec Kralove, Hradec Králové

Fakultni nemocnice v Motole, Prague

Vseobecna fakultni nemocnice v Praze, Prague

CHU Angers - Hôpital Hôtel Dieu, Angers

Hôpital Henri Mondor, Créteil

Hopital Claude Huriez - CHRU Lille, Lille

Hopital de la Conception - APHM, Marseille

CHU de Nantes - Hotel Dieu, Nantes

Hôpital Saint-Antoine, Paris

Hôpital Saint-Louis, Paris

CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac

CHU Amiens - Hopital Sud, Salouël

CHU Tours - Hôpital Bretonneau, Tours

Universitaetsklinikum Freiburg, Freiburg im Breisgau

Universitaetsklinikum Aachen AOeR, Aachen

Vivantes Klinikum Neukoelln, Berlin

Universitaetsklinikum Wuerzburg, Würzburg

Clinica di Ematologia AOU Ospedali Riuniti di Ancona, Ancona

IRCCS Centro di Riferimento Oncologico, Aviano

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili), Brescia

Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo

"IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori - IRST", Meldola

IEO Istituto Europeo di Oncologia Parent, Milan

Ospedale San Raffaele, Milan

Azienda Ospedaliera Vincenzo Cervello, Palermo

AUSL Piacenza Ospedale Guglielmo da Saliceto, Piacenza

Azienda sanitaria integrata università di Trieste, Trieste

Kyushu University Hospital, Fukuoka

Kagoshima University Hospital, Kagoshima

Kanazawa University Hospital, Kanazawa

National Cancer Center Hospital East, Kashiwa

Cancer Institute Hospital of JFCR, Kōtoku

Matsuyama Red Cross Hospital, Matsuyama

NHO Nagoya Medical Center, Nagoya

Kindai University Hospital, Ōsaka-sayama

Yamagata University Hospital, Yamagata

Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej, Biała Podlaska

Pratia MCM Krakow, Krakow

Centrum Medyczne Pratia Poznan, Skorzewo

MICS Centrum Medyczne Torun, Torun

Keimyung University Dongsan Hospital, Daegu

National Cancer Center, Goyang-si

Jeonbuk National University Hospital, Jeonju

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

ICO Badalona - Hospital Universitari Germans Trias i Pujol, Badalona

Hospital Clinic de Barcelona, Barcelona

ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona

Hospital San Pedro de Alcantara, Cáceres

Hospital General Universitario Gregorio Marañon, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Fundacion Jimenez Diaz, Madrid

Hospital Universitario Ramon y Cajal, Madrid

Hospital Universitario Nuestra Señora de Valme, Seville

Hospital Universitario Puerta del Mar, Seville

Hospital Universitario Virgen Macarena, Seville

Royal Marsden Hospital - Fulham, London

Derriford Hospital, Plymouth

Southampton General Hospital, Southampton

Royal Marsden Hospital, Sutton

Royal Cornwall Hospital NHS Trust, Truro

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Genmab

INDUSTRY